Concepta PLC Assembly held in Shanghai to showcase myLotus
14 December 2017 - 6:01PM
RNS Non-Regulatory
TIDMCPT
Concepta PLC
14 December 2017
14 December 2017
Concepta plc
("Concepta" or the "Company")
Assembly held in Shanghai to showcase myLotus product
Hospital evaluation results of myLotus exceeded expectations
Excellent reception from potential distributors
Concepta plc (AIM: CPT), the UK healthcare company and developer
of a proprietary product targeted at the mobile health market with
a primary focus on women's fertility, is pleased to announce that
it held its inaugural meeting to present its myLotus fertility
product to potential distributors in Shanghai on 22 November
2017.
Concepta executives, alongside Chinese hospital partners, gave
presentations on both the Company and its myLotus product,
consisting of the myLotus meter, testing strips and app.
Leading doctors from both the Changhai and HuaShan hospitals
also presented results of a hospital evaluation of the Company's
myLotus product. The results concluded that the LH and hCG(2)
measurements registered by myLotus achieved approximately 100%
correlation with those of hospital laboratory tests carried out on
blood samples. The results presented strong evidence of the
product's effectiveness to distributors, who will now assess the
hospital route-to-market for myLotus.
31 potential distributors attended the meeting, covering 14
important cities and provinces(1) , including Beijing and Shanghai.
Between them these distributors cover a total population of over
800 million people and have the potential to reach an estimated 2.8
million women with unexplained infertility.
Erik Henau, CEO of Concepta commented: "With our distributor
network in China expected to grow significantly next year, we
intend to expand both of our UK and China based manufacturing sites
to ramp up production. We have conducted an extensive review to
ensure that the supply chain is operating at an optimum level to
meet demand, and we will continue to adjust as demand
increases.
"We are extremely pleased with the reception that our myLotus
product received at the meeting. Over the coming months, Concepta's
team in China will be presenting full product demonstrations at the
premises of each of the potential distributors as they prepare
their business plans for their province.
"We anticipate 2018 to be a transformational year in which we
build our distribution network throughout China as well as our
direct to consumer launch in Europe, and look forward to updating
the market on these developments in the New Year."
(1) The distributors in attendance covered Beijing, Shanghai,
Tianjin, FuJian, ShanDong, HeNan, JiangSu, GuangDong, ShangXi,
ChongQing, JiLin, AnHui, YunNan and HuBei
(2) LH and hCG are hormones that directly influence a woman's
fertility
Enquiries:
The Company
Erik Henau
CEO
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7382 8300
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
About Concepta Plc:
Concepta plc is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus, targeted at the
personalised mobile health market with a primary focus on
unexplained infertility* in women.
myLotus is currently the only consumer product which allows both
quantitative and qualitative measurements of a woman's personal LH
and hCG* hormone levels in a home test, facilitating higher
conception rates and early diagnosis of issues with fertility
hormones. The proposition of myLotus is to help women conceive
naturally.
Concepta has made significant progress recently, establishing
agreements with a number of distributors in China where myLotus has
been given cFDA approval. Concepta is initially targeting the
traditional route to market in China through Chinese hospitals and
plans to add the direct-to-consumer route in the near future.
The Company is also well on its way to achieving CE-marking and
commencing its direct-to-consumer launch in the UK and Europe in H1
2018. The Company has identified a significant global market
opportunity, with revenue potential of the Chinese and EU
unexplained infertility market estimated to be worth c.GBP600m per
annum.
*Unexplained infertility refers to women that have been unable
to conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases such as
marketing messages, corporate and product information into the
public domain. An RNS Regulatory announcement is required to be
notified under the AIM Rules for Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMMMMZFFRGNZZ
(END) Dow Jones Newswires
December 14, 2017 02:01 ET (07:01 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024